P. M. Machado, “Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis”, rrnmf, vol. 5, no. 2, Sep. 2024, doi: 10.17161/rrnmf.v4i5.16244.